IMMU — Mendus AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK431.57m
- SEK334.43m
- 17
- 47
- 21
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.61 | ||
| Price to Tang. Book | 2.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.85% | ||
| Return on Equity | -16.67% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | 1.79 | n/a | n/a | 176 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Directors
- Christine Lind NEC (47)
- Erik Manting CEO (50)
- Lotta Ferm CFO (55)
- Alex Karlsson-Parra CSO (71)
- Jeroen Rovers OTH (51)
- Sven Andreasson IND (69)
- Dharminder Chahal IND (45)
- Charlotte Edenius IND (63)
- Steven Glazer IND (73)
- Helen Tuvesson IND (59)
- Andrea van Elsas IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 9th, 2002
- Public Since
- April 22nd, 2013
- No. of Employees
- 30
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 863,148,371
- Address
- Ostermalmstorg 5, STOCKHOLM, 111 53
- Web
- https://mendus.com/
- Phone
- +46 87328400
- Auditors
- Ernst & Young AB
Upcoming Events for IMMU
Mendus AB (publ) Annual Shareholders Meeting
Q1 2024 Mendus AB (publ) Earnings Release
Q2 2024 Mendus AB (publ) Earnings Release
Similar to IMMU
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
What is the Mendus AB (publ) share price?
As of Today at 19:14 UTC, shares in Mendus AB (publ) are trading at SEK0.50. This share price information is delayed by 15 minutes.
How has the Mendus AB (publ) share price performed this year?
Shares in Mendus AB (publ) last closed at SEK0.50 and the price had moved by -70.3% over the past 365 days. In terms of relative price strength the Mendus AB (publ) share price has underperformed the FTSE Global All Cap Index by -72.12% over the past year.
What are the analyst and broker recommendations for Mendus AB (publ)?
The overall consensus recommendation for Mendus AB (publ) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Mendus AB (publ) dividend yield?
Mendus AB (publ) does not currently pay a dividend.
Does Mendus AB (publ) pay a dividend?
Mendus AB (publ) does not currently pay a dividend.
When does Mendus AB (publ) next pay dividends?
Mendus AB (publ) does not currently pay a dividend.
How do I buy Mendus AB (publ) shares?
To buy shares in Mendus AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mendus AB (publ)?
As of the previous close price of SEK0.50, shares in Mendus AB (publ) had a market capitalisation of SEK431.57m.
Where are Mendus AB (publ) shares listed?
Here are the trading details for Mendus AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: IMMU
What kind of share is Mendus AB (publ)?
Based on an overall assessment of its quality, value and momentum Mendus AB (publ) is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mendus AB (publ) share price forecast for 2024?
The analyst consensus target price for shares in Mendus AB (publ) is SEK1.25. That is 150% above the last closing price of SEK0.50.
Analysts covering Mendus AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.12 for the next financial year.
What is the trend in the Mendus AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mendus AB (publ). Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +3.19%.
As of the last closing price of SEK0.50, shares in Mendus AB (publ) were trading +7.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mendus AB (publ) PE Ratio?
The Mendus AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mendus AB (publ)?
Mendus AB (publ)'s management team is headed by:
- Christine Lind - NEC
- Erik Manting - CEO
- Lotta Ferm - CFO
- Alex Karlsson-Parra - CSO
- Jeroen Rovers - OTH
- Sven Andreasson - IND
- Dharminder Chahal - IND
- Charlotte Edenius - IND
- Steven Glazer - IND
- Helen Tuvesson - IND
- Andrea van Elsas - IND